Holen Sie sich die Stockscreener-App
64.23
1.28%
0.81
Handel nachbörslich:
64.27
0.04
+0.06%
Schlusskurs vom Vortag:
$63.42
Offen:
$64.08
24-Stunden-Volumen:
12.09M
Relative Volume:
0.74
Marktkapitalisierung:
$95.46B
Einnahmen:
$20.08B
Nettoeinkommen (Verlust:
$2.89B
KGV:
33.12
EPS:
1.9391
Netto-Cashflow:
$3.66B
1W Leistung:
+3.95%
1M Leistung:
-9.79%
6M Leistung:
-35.28%
1J Leistung:
-32.47%
1-Tages-Spanne:
$63.90
$64.89
1-Wochen-Bereich:
$61.44
$65.56
52-Wochen-Spanne:
$60.59
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
64.23 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
ABT
Abbott Laboratories
|
96.81 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
343.32 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.19 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
80.99 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | Herabstufung | Erste Group | Buy → Hold |
| 2025-09-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Scientific Shares Gain Following Positive Heart Implant Study - HarianBasis.co
Here’s What Piper Sandler Thinks About Boston Scientific Corp (BSX) Now - Yahoo Finance
Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
ROSEN, THE FIRST FILING FIRM, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Boston Scientific Advances Fainting Detection Study With New Wearable Data Initiative - TipRanks
Boston Scientific Corporation $BSX Position Lifted by Ninety One UK Ltd - MarketBeat
Boston Scientific Corp (NYSE:BSX) Presents a Compelling Growth and Technical Setup Case - ChartMill
Asset Management One Co. Ltd. Increases Stock Position in Boston Scientific Corporation $BSX - MarketBeat
AE Wealth Management LLC Boosts Stake in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Boston Scientific Corp Investor Event at the Scientific Session of the American College of Cardiology Transcript - GuruFocus
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class ActionBSX - TMX Newsfile
Boston Scientific Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Boston Scientific Corporation (BSX) Price Target Lowered at Mizuho Ahead of Q1 Medical Device Earnings - Insider Monkey
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
BSX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - Barchart.com
Boston Scientific: The Company That Never Turned Around - Yahoo
INVESTOR DEADLINE: Boston Scientific Corporation (BSX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - The Malaysian Reserve
Analysts Bullish on Boston Scientific (BSX) Amid Expectations for 30% YoY Growth in 2026 - Insider Monkey
BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Electrophysiology Procedure Growth - marketscreener.com
Boston Scientific plans $88.5M R&D expansion in Ireland - Yahoo Finance
Boston Scientific Corporation $BSX Position Increased by KBC Group NV - MarketBeat
Boston Scientific (BSX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit - ChartMill
Boston Scientific Corp (BSX-N) Stock Price and News - The Globe and Mail
Truist cuts Boston Scientific stock price target on Watchman concerns By Investing.com - Investing.com South Africa
Truist cuts Boston Scientific stock price target on Watchman concerns - Investing.com
BSX Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Truist Financial Cuts Boston Scientific (NYSE:BSX) Price Target to $90.00 - MarketBeat
Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Baird Adjusts Boston Scientific Price Target to $86 From $95, Maintains Outperform Rating - marketscreener.com
Truist Trims Price Target on Boston Scientific to $90 From $92, Keeps Buy Rating - marketscreener.com
Boston Scientific invests €75m in Galway site - Business Post
Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX - ChartMill
Boston Scientific Corp. stock rises Tuesday, still underperforms market - MarketWatch
Cardiac Monitoring Devices Market Set for Sustained Growth at 5.17% CAGR Through 2034: DelveInsight | Philips, Medtronic, and Boston Scientific - Barchart.com
Citi Reiterates Buy rating for Boston Scientific (BSX) - Yahoo Finance
Boston Scientific Corp. stock (US10117L1017): Is medtech innovation strong enough to unlock new upsi - AD HOC NEWS
BOSTON SCIENTIFIC CORPORATION (BSX) DEADLINE ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline - TMX Newsfile
Fund Update: 486,715 BOSTON SCIENTIFIC (BSX) shares added to Bank Pictet & Cie (Europe) AG portfolio - Quiver Quantitative
BSX Shareholder Alert: Boston Scientific Corporation Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - Barchart.com
RBC Cuts Price Target on Boston Scientific to $105 From $115, Keeps Outperform Rating - marketscreener.com
Faruqi & Faruqi, LLP Highlights Class Action Against Boston Scientific (BSX) and Upcoming Lead Plaintiff Deadline of May 4, 2026 - marketscreener.com
Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Portnoy Law Firm Announces Class Action on Behalf of Boston Scientific Corporation Investors - GlobeNewswire
Sumitomo Mitsui Trust Group Inc. Trims Stock Position in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation $BSX Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):